ALB and infection: Except in type C ACLF, a gradual decline in both platelet count and albumin levels, along with a slow increase in lactate after treatment, predict poor outcomes and increased risk of hypotension, bleeding, shock, infection, and hepatic encephalopathy during future artificial liver therapy.